Celltrion

Dear Valued Shareholders,

On Thursday, May 15, 2025, Celltrion Group Chairman Jung Jin Seo held an online meeting with domestic and international journalists, analysts, and institutional investors. During the session, he personally addressed the company’s strategic response to rapid changes in the global biopharmaceutical market, including recent shifts in U.S. pharmaceutical policy, and shared the company’s outlook for 2025. This event served as a timely opportunity to reduce market uncertainties.
 

Celltrion remains firmly committed to its core principles and continuous efforts to enhance shareholder value. Our future plans in this regard are outlined below:

■ Shareholder Meeting Scheduled for Late May
 

We will hold a separate shareholder meeting at the end of May, presided over by the CEO. This meeting reflects our sincere intention to communicate transparently with our shareholders. Preparations are currently underway, and we will promptly provide further details once finalized.
 

■ Ongoing Share Buybacks and Executive Share Purchases
 

So far this year, we have acquired treasury shares worth KRW 450 billion to help stabilize the market. We will continue monitoring the market and consider additional buybacks if necessary. In addition, key executives across Celltrion Group, including Celltrion Holdings, plan to purchase company shares, and employee participation through the Employee Stock Ownership Plan (ESOP) is also set to proceed. These initiatives reflect the voluntary commitment of our organization to participate in market stabilization efforts. If needed, additional executive share purchases will also be considered.
 

■ Strengthened Global Sales Efforts
 

Personnel across our global subsidiaries and the Global Sales Business Group remain fully dedicated to driving operational excellence and delivering improved performance across key markets. The company will continue to extend its full support to ensure these initiatives contribute meaningfully to our objectives. Furthermore, our senior leadership will visit overseas markets in person to oversee frontline sales activities and reinforce our commitment to sales growth.
 

We remain dedicated to improving our business performance and stabilizing our stock price.
 

Lastly, we would like to make one request to our valued shareholders.
 

Recently, there has been a sharp increase in stock lending (securities lending) transactions. Excessive lending can be used for short selling, which may hinder our efforts to stabilize the share price and delay the positive outcomes we and our shareholders are striving for.
 

We therefore respectfully ask shareholders who have lent out their shares to consider recalling them. If you receive requests for stock lending, we urge you to consider them carefully before proceeding. Your support is vital in helping Celltrion pursue long-term growth and enhance corporate value.
 

Thank you once again for your continued trust and support.